Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies

Clinical Therapeutics

Volumn 38, Issue 9, 2016, Pages 2083-2097.e7

  Nagy, Christa F ^a   Leach, Timothy S ^b   Hoffman, Joseph H ^c   Czech, Arthur ^a   Carpenter, Sarah E ^a   Guttendorf, Robert ^d  

^a Elusys Therapeutics Inc   (United States)

^b InterimMD   (United States)

^c Hoffman Consulting LLC   (United States)

^d Aclairo Pharmaceutical Development Group Inc   (United States)

Author keywords

animal rule; anthrax; monoclonal antibody; obiltoxaximab; pharmacokinetic properties

Indexed keywords

CIPROFLOXACIN; DIPHENHYDRAMINE; EPINEPHRINE; FAMOTIDINE; METHYLPREDNISOLONE; OBILTOXAXIMAB; PLACEBO; ANTITOXIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BRONCHOSPASM; CONTROLLED STUDY; COUGHING; CYANOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; HYPOXIA; IMMUNOGENICITY; INJECTION SITE SWELLING; LACERATION; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; MYALGIA; NORMAL HUMAN; NOSE OBSTRUCTION; OPEN STUDY; OROPHARYNX PAIN; PARALLEL DESIGN; PHARMACOKINETIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; POSITIONAL DIZZINESS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SINGLE DRUG DOSE; SKIN BRUISING; THORAX PAIN; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; URTICARIA; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG HYPERSENSITIVITY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTITOXINS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; HALF-LIFE; HEADACHE; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84988624678     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.07.170     Document Type: Article

References (24)

1. 1 Mock, M., Fouet, A., Anthrax. Annu Rev Microbiol 55 (2001), 647–671.
2. 2 Dixon, T.C., Meselson, M., Guillemin, J., Hanna, P.C., Anthrax. N Engl J Med 341 (1999), 815–826.
3. 3 Guarner, J., Jernigan, J.A., Shieh, W.J., et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 163 (2003), 701–709.
4. 4 Holty, J.E., Bravata, D.M., Liu, H., Olshen, R.A., et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 144 (2006), 270–280.
5. 5 Anthrax in Humans and Animals., 4th ed, 2008, World Health Organization, Geneva, Switzerland.
6. 6 Veitch, J., Kansara, A., Bailey, D., Kustos, I., Severe systemic Bacillus anthracis infection in an intravenous drug user. BMJ Case Rep, 2014, 2014.
7. 7 Inglesby, T.V., O׳Toole, T., Henderson, D.A., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287 (2002), 2236–2252.
8. 8 Hendricks, K.A., Wright, M.E., Shadomy, S.V., et al. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis, 20, 2014.
9. 9 Jernigan, J.A., Stephens, D.S., Ashford, D.A., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7 (2001), 933–944.
10. 10 Bower, W.A., Hendricks, K., Pillai, S., et al. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident. MMWR Recomm Rep 64 (2015), 1–22.
11. 11 Mock, M., Roques, B.P., Progress in rapid screening of Bacillus anthracis lethal factor activity. Proc Natl Acad Sci U S A 99 (2002), 6527–6529.
12. 12 Singh, Y., Klimpel, K.R., Goel, S., Swain, P.K., et al. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect Immun 67 (1999), 1853–1859.
13. 13 O׳Brien, J., Friedlander, A., Dreier, T., Ezzell, J., et al. Effects of anthrax toxin components on human neutrophils. Infect Immun 47 (1985), 306–310.
14. 14 Hoover, D.L., Friedlander, A.M., Rogers, L.C., Yoon, I.K., et al. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun 62 (1994), 4432–4439.
15. 15 Rossi, C.A., Ulrich, M., Norris, S., Reed, D.S., et al. Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax. Infect Immun 76 (2008), 5790–5801.
16. 16 Mohamed, N., Clagett, M., Li, J., et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 73 (2005), 795–802.
17. 17 Yamamoto BJ, Carpenter S, Sanford D, et al. Obiltoxaximab for inhalational anthrax: efficacy projection across a range of disease severity. Antimicrob Agents Chemother In Press.
18. 18 Guttendorf, R., Mondick, J, Serbina, N., et al. Animal to human dose translation under the Animal Rule - obiltoxaximab (ETI-204) case study. 2016, ASM Biodefense and Emerging Diseases Research Meeting, Arlington, VA.
19. 19 Davies, B., Morris, T., Physiological parameters in laboratory animals and humans. Pharm Res 10 (1993), 1093–1095.
20. 20 Wang, W., Wang, E.Q., Balthasar, J.P., Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84 (2008), 548–558.
21. 21 Sampson, H.A., Munoz-Furlong, A., Campbell, R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117 (2006), 391–397.
22. 22 Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (Accessed June 27, 2016, at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.).
23. 23 Anthim [package insert]. Pine Knoll. 2016, Elusys Therapeutics, Inc, NJ.
24. 24 FDA Product Development Under the Animal Rule: Guidance for Industry. Silver Spring, MD: US Department of Health and Human Servies Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluaiton and Research (CBER); 2015.